HomeNTRA • NASDAQ
add
Natera Inc
Previous close
$236.49
Day range
$236.53 - $241.28
Year range
$125.38 - $241.28
Market cap
33.02B USD
Avg Volume
1.59M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 592.18M | 34.66% |
Operating expense | 481.96M | 54.93% |
Net income | -87.54M | -177.11% |
Net profit margin | -14.78 | -105.85% |
Earnings per share | -0.64 | -146.15% |
EBITDA | -87.28M | -180.31% |
Effective tax rate | -0.24% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.04B | 13.02% |
Total assets | 1.82B | 14.49% |
Total liabilities | 569.29M | -20.09% |
Total equity | 1.25B | — |
Shares outstanding | 138.01M | — |
Price to book | 25.99 | — |
Return on assets | -13.63% | — |
Return on capital | -16.86% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -87.54M | -177.11% |
Cash from operations | 59.39M | 14.68% |
Cash from investing | -19.90M | -146.79% |
Cash from financing | 1.94M | 12.50% |
Net change in cash | 41.42M | -56.88% |
Free cash flow | 71.33M | 77.49% |
About
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments in San Carlos, California and Austin, Texas. Wikipedia
Founded
Jan 1, 2004
Headquarters
Website
Employees
4,429
